Compare Sanofi SA (SNY) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Consumer Staples Select Sector SPDR Fund — how do they compare? Sanofi SA trades at $43.14 (market cap $104.06B), while Consumer Staples Select Sector SPDR Fund trades at $83.19. The key difference: Sanofi SA pays a 5.61% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | XLP | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | — |
52-Week High | $52.34 | $90.00 |
52-Week Low | $41.33 | $75.61 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.02, down 0.66% on the day amid broader market volatility. The technical picture shows bearish momentum with selling pressure outweighing buying signals 14 to 6, though oscillators suggest potential stabilization. Analyst consensus remains strongly positive with 100% buy ratings, highlighting XLP's defensive characteristics during economic uncertainty. Recent news emphasizes the fund's appeal as a safe haven with its 2.6% dividend yield and exposure to stable consumer staples companies.
XLP offers defensive exposure to essential consumer goods companies, providing stability during market turbulence. The fund's low 0.08% expense ratio and consistent dividend payments support its appeal for risk-averse investors. However, limited growth potential compared to cyclical sectors and sensitivity to consumer spending trends present ongoing challenges for significant price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
